Ascendis Pharma announced that the FDA has accepted its New Drug Application for TransCon CNP, a treatment for children with achondroplasia, for priority review.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia, a rare ...

Shares of Ascendis Pharma AS (NASDAQ:ASND) rose 5.8% after the U.S. Food and Drug Administration (FDA) accepted the company’s ...

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.

The Ascendis Pharma A/S-Bond has a maturity date of 4/1/2028 and offers a coupon of 2.2500%. The payment of the coupon will take place 2,0 times per biannual on the 01.10.. The Ascendis Pharma A/S ...

Under the terms of the alliance, Ascendis will carry out the early development of TransCon product candidates, funded by Novo Nordisk, with the pharma group taking over once they reach the ...

Get the detailed quarterly/annual income statement for Ascendis Pharma A/S (ASND). Find out the revenue, expenses and profit or loss over the last fiscal year.

One of the most significant benefits of digital health devices to pharma clinical trials is the ability to continuously and objectively monitor biological data. Prior to these technologies ...

BioMarin Pharmaceutical Inc., a biotechnology company ... a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The logo of Sanofi is seen at the French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile, near Lyon, France, September 30, 2023. REUTERS/Gonzalo Fuentes/File Photo France's Sanofi ...

Decent at the right price. Our research team assigns Neutral ratings to strategies they’re not confident will outperform a relevant index, or most peers, over a market cycle on a risk-adjusted ...